Related Experiment Video
Updated: May 16, 2026

A Culture Method to Maintain Quiescent Human Hematopoietic Stem Cells
Published on: May 17, 2021
Ferrostatin-1 and hinokitiol supplementation enhance human hematopoietic stem cell expansion in a chemically defined
1Tumor Vaccine and Biotechnology Branch, Division of Cell Therapy 2, Office of Cellular Therapy and Human Tissue, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
An optimized and standardized method for ex vivo expansion of cord blood (CB) hematopoietic stem cells (HSCs) in a chemically defined medium has yet to be established. In this study, we aimed to improve ex vivo expansion of HSCs in a recently developed cytokine-free, chemically defined 3a medium. We found that the co-supplementation of the ferroptosis inhibitor ferrostatin-1 and iron chelator hinokitiol (FHK) in 3a medium significantly improves CB HSC expansion by suppressing lipid peroxidation and mitigating oxidative stress. FHK supplementation improves overall cell proliferation and promotes preferential expansion of HSCs without adversely affecting the clonogenic, engraftment, and differentiation potential of HSCs. The delayed engraftment kinetics with gradual increase in hematopoietic output further suggests that FHK treatment may preserve or expand long-term HSCs. Our findings are in alignment with recent published studies highlighting the susceptibility of HSCs to ferroptosis and corroborate the use of antioxidants to improve ex vivo expansion of HSC.
An optimized and standardized method for ex vivo expansion of cord blood (CB) hematopoietic stem cells (HSCs) in a chemically defined medium has yet to be established. In this study, we aimed to improve ex vivo expansion of HSCs in a recently developed cytokine-free, chemically defined 3a medium. We found that the co-supplementation of the ferroptosis inhibitor ferrostatin-1 and iron chelator hinokitiol (FHK) in 3a medium significantly improves CB HSC expansion by suppressing lipid peroxidation and mitigating oxidative stress. FHK supplementation improves overall cell proliferation and promotes preferential expansion of HSCs without adversely affecting the clonogenic, engraftment, and differentiation potential of HSCs. The delayed engraftment kinetics with gradual increase in hematopoietic output further suggests that FHK treatment may preserve or expand long-term HSCs. Our findings are in alignment with recent published studies highlighting the susceptibility of HSCs to ferroptosis and corroborate the use of antioxidants to improve ex vivo expansion of HSC.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Multipotency of Hematopoietic Stem Cells

